XBody Health & Wellness in Wayne, NJ is now offering the pTau-217 blood test — the first and only FDA-approved blood-based diagnostic tool for Alzheimer’s disease. This breakthrough test marks a significant advancement in early detection, offering patients a less invasive, more accessible alternative to traditional diagnostic procedures like PET scans and lumbar punctures.
What Is the pTau-217 Test?
Alzheimer’s disease is characterized by the buildup of proteins in the brain, particularly phosphorylated tau (pTau). One specific form, pTau-217, is considered a highly specific biomarker for Alzheimer’s-related changes, even in the earliest stages of disease progression.
The pTau-217 blood test works by measuring the concentration of this protein in the bloodstream, helping clinicians determine whether a person is at low, intermediate, or high risk of Alzheimer’s pathology. Because it can detect signs well before severe symptoms arise, this test is a major step forward in proactive brain health care.
How the Test Works
The process is simple, quick, and non-invasive:
- A standard blood draw is performed on-site by our trained clinical staff.
- The sample is analyzed to determine levels of pTau-217 in the blood.
- Results fall into one of three clinical categories:
- < 0.34 ng/L – Low likelihood of Alzheimer’s disease
- 0.34–0.63 ng/L – Intermediate zone
- > 0.63 ng/L – High likelihood of Alzheimer’s disease
Results are reviewed by our functional wellness team and interpreted within the broader context of your health history, symptoms, and any cognitive concerns you may be experiencing. From there, personalized next steps can be determined.
Why Early Detection Matters
Alzheimer’s is a progressive neurodegenerative disease, and the earliest changes in the brain can begin up to 20 years before symptoms become noticeable. Detecting those changes early provides a crucial opportunity to:
- Monitor disease progression more effectively
- Plan long-term care and support
- Introduce lifestyle, nutritional, and cognitive interventions that may slow decline
- Offer clarity and direction to individuals experiencing unexplained memory issues
The ability to identify elevated pTau-217 levels gives both patients and providers an evidence-based foundation for decision-making — without the need for costly imaging or uncomfortable spinal taps.
Who Should Consider This Test?
The pTau-217 blood test may be appropriate for individuals who:
- Have a family history of Alzheimer’s or dementia
- Are experiencing early cognitive symptoms, such as forgetfulness or difficulty concentrating
- Want a non-invasive, evidence-based way to assess Alzheimer’s risk
- Are navigating complex neurological symptoms and need additional clarity
- Are developing a proactive cognitive wellness plan
It’s important to understand that this test does not diagnose Alzheimer’s disease on its own. Instead, it provides critical insight into whether the biological hallmarks of Alzheimer’s may be present — information that can help guide further evaluation, intervention, or preventive care.
XBody Health & Wellness is committed to delivering comprehensive diagnostic tools that empower patients to take control of their health — physically, cognitively, and emotionally. Offering the pTau-217 test reflects our belief that knowledge is power, especially when it comes to brain health.
By making this cutting-edge test available in-office, we’re helping individuals and families get answers faster, more affordably, and with less stress.
If you or a loved one are experiencing changes in memory, or if you’re simply looking to be proactive about brain health, the pTau-217 test is a meaningful first step.
Schedule your consultation or blood draw appointment at XBody Health & Wellness today. Our team is here to walk you through the process, review your results, and support your long-term cognitive wellness journey.
